Rein Therapeutics (RNTX) AI Stock Analysis

• Market Cap: $32.07M
• Dividend Yield: N/A
• Average Volume (3M): 228.95K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.42
• Revenue Growth: N/A
• EPS Growth: 15.35%
• Country: US
• Employees: 11
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): -0.21
• Shares Outstanding: 26,286,383
• 10 Day Avg. Volume: 262,542
• 30 Day Avg. Volume: 228,948
• PEG Ratio: >-0.01
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: 2.22
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -1.17
• 1Y Price Target: $8.00
• Price Target Upside: 534.92% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $1.00 ▼(-20.63% Downside)

The score is held down primarily by weak financial performance (no revenue, sizable losses, and persistent cash burn) and a bearish technical setup (below key moving averages with negative MACD). A meaningful offset is the positive corporate event (FDA lift of the clinical hold), while valuation provides limited support due to ongoing losses and no dividend.

Positive Factors

Regulatory Approval

The MHRA approval for the Phase 2 trial of LTI-03 indicates progress in drug development, potentially leading to new revenue streams and strengthening the company's market position in the long term.

No Leverage Risk

The absence of debt reduces financial risk, providing Rein Therapeutics with greater flexibility to invest in growth opportunities and withstand economic fluctuations.

New Financial Agreements

Securing new financing agreements enhances liquidity, enabling Rein Therapeutics to fund ongoing operations and support strategic initiatives, potentially improving long-term financial stability.

Negative Factors

Persistent Negative Cash Flow

Ongoing negative cash flows indicate operational inefficiencies and a lack of sustainable cash generation, which could hinder Rein Therapeutics' ability to finance future growth and innovation.

Declining Equity

The significant decline in equity reflects financial instability, limiting Rein Therapeutics' ability to absorb losses and invest in long-term growth, potentially affecting its competitive position.

Lack of Revenue

The absence of revenue-generating activities raises concerns about Rein Therapeutics' business model viability and its ability to achieve profitability, impacting its long-term sustainability.

Rein Therapeutics Business Overview & Revenue Model

Company Description

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

How the Company Makes Money

Rein Therapeutics Financial Statement Overview

Summary

Rein Therapeutics faces significant challenges in achieving revenue generation and profitability, as evidenced by the persistent negative net income and cash flows. Despite the absence of debt, the declining equity and negative cash flows suggest financial strain. The company needs to focus on developing revenue-generating operations to improve its financial health and sustainability.

Income Statement

Rein Therapeutics has consistently reported zero total revenue over the years, indicating the absence of revenue-generating activities. Additionally, the company has experienced significant net losses, with increasing net losses from $21.8 million in 2020 to $62.9 million in 2024. The EBITDA margin has also been negative, reflecting operational inefficiencies. The lack of revenue growth and persistent losses are concerning for the company's income statement.

Balance Sheet

The company's balance sheet shows a relatively low level of total debt, with zero debt reported in 2024, indicating no leverage risk. However, the stockholders' equity has been fluctuating, with a significant decrease from $43.9 million in 2021 to $9.4 million in 2024. The equity ratio has also declined, reflecting a reduction in financial stability. Despite the absence of debt, the diminishing equity base raises concerns about the company's long-term solvency.

Cash Flow

Rein Therapeutics has consistently reported negative operating and free cash flows, indicating cash outflows exceeding cash inflows from operations. Although there was a noticeable inflow from financing activities in recent years, operating cash flow to net income ratios are negative due to ongoing operational losses. The lack of free cash flow growth highlights challenges in generating sustainable cash flows.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-60.59M	-28.05M	-15.23K	-27.48K	-26.48K	-20.33K
Net Income	-58.88M	-62.88M	-15.73K	-27.33K	-26.16K	-21.16K
Balance Sheet
Total Assets	53.71M	69.24M	106.01M	22.01M	48.48M	16.34M
Cash, Cash Equivalents and Short-Term Investments	4.05M	12.87M	17.31M	21.24M	45.93M	13.80M
Total Debt	0.00	0.00	48.00K	33.00K	162.00K	387.00K
Total Liabilities	7.52M	14.85M	99.12M	3.38M	4.58M	4.18M
Stockholders Equity	46.19M	54.39M	6.89M	18.62M	43.90M	12.16M
Cash Flow
Free Cash Flow	-20.95M	-22.29M	-19.81M	-24.86M	-23.91M	-20.48M
Operating Cash Flow	-20.95M	-22.29M	-19.81M	-24.86M	-23.75M	-20.48M
Investing Cash Flow	0.00	0.00	16.20M	26.46M	-35.92M	6.41M
Financing Cash Flow	7.35M	17.82M	15.79M	0.00	55.66M	15.80M

Rein Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNTX, the sentiment is Negative. The current price of 1.26 is below the 20-day moving average (MA) of 1.31, below the 50-day MA of 1.40, and below the 200-day MA of 1.48, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 43.62 is Neutral, neither overbought nor oversold. The STOCH value of 59.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RNTX.

Rein Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KZR	52 Neutral	$47.60M	-0.77	-56.86%	―	―	35.80%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RNTX	48 Neutral	$32.07M	-0.46	-83.28%	―	―	15.35%
VVOS	48 Neutral	$19.95M	-1.12	-335.47%	―	18.76%	60.09%
OKUR	42 Neutral	$38.75M	-0.46	-115.64%	―	―	46.20%
RANI	41 Neutral	$168.91M	―	―	―	―	25.08%

Rein Therapeutics Corporate Events

Rein Therapeutics Ends Key Financial Agreements

On December 11, 2025, Rein Therapeutics, Inc. decided to terminate its Pre-Paid Advance Agreement and Standby Equity Purchase Agreement with YA II PN, Ltd., a Cayman Islands exempt limited partnership. The company had previously received $3 million in advances under the PPA, with the last advance taken on October 23, 2025, but did not sell any common stock under the SEPA. The termination of these agreements did not result in any penalties or fees for the company.

The most recent analyst rating on (RNTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Rein Therapeutics stock, see the RNTX Stock Forecast page.

Rein Therapeutics Resumes Phase 2 Trial for LTI-03

On November 3, 2025, Rein Therapeutics announced that the FDA has lifted the clinical hold on their Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis, allowing the company to resume U.S. enrollment in late 2025 or early 2026. This clearance is a significant milestone for Rein, as early data suggests LTI-03 may not only slow fibrosis but also promote lung healing, potentially impacting the treatment landscape for IPF. The trial will be conducted across approximately 20 U.S. sites and is part of a broader global study, with initial topline data expected in Q3 2026.

The most recent analyst rating on (RNTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Rein Therapeutics stock, see the RNTX Stock Forecast page.

Rein Therapeutics Secures Third Pre-Paid Advance

On July 29, 2025, Rein Therapeutics entered into a Pre-Paid Advance Agreement with YA II PN, Ltd., allowing the company to request up to $6.0 million in pre-paid advances over a year. The agreement stipulates that advances will be purchased at 95% of their face value, with interest accruing at 8% annually, increasing to 18% upon default. On October 23, 2025, Rein Therapeutics received a third pre-paid advance of $1.0 million from Yorkville, with net proceeds of $0.95 million, as part of a private placement exempt from registration under the Securities Act of 1933.

The most recent analyst rating on (RNTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Rein Therapeutics stock, see the RNTX Stock Forecast page.